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Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR, HER1/ErbB1) tyrosine kinase, has been shown to have clinical
activity against non-small-cell lung cancers (NSCLCs), especially in women nonsmokers with adenocarcinomas. The aim of the
present study was to clarify the relationship between androgen levels and gefitinib treatment in patients with advanced NSCLCs. Sera
from 67 cases (36 men and 31 women) were obtained pretreatment and during treatment with gefitinib monotherapy (days 14–18)
for examination of testosterone, dehydroepiandrosterone sulphate (DHEA), and dehydroepiandrosterone sulphate (DHEAS) levels.
Testosterone and DHEA during treatment were significantly lower than the pretreatment values in both women and men, and the
DHEAS levels during treatment were also significantly lowered in women. Gefitinib treatment significantly suppressed androgen
levels, especially in women who had no smoking history. In addition, hormone levels in women responding to gefitinib were
significantly lower during the treatment than in women who did not respond. Gefitinib-associated decrease in serum androgen levels
may play a role in its clinical efficacy.
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Non-small-cell lung cancer (NSCLC) is a major health problem
worldwide for both men and women (Ferlay et al, 2001). Usually
at the time of diagnosis more than 50% of the patients have ad-
vanced or metastatic disease. While cytotoxic chemotherapy
slightly prolongs survival among advanced NSCLC patients, it
exerts clinically significant adverse effects (Non-Small-Cell Lung
Cancer Collaborative Group, 1995; Schiller et al, 2002). An
effective, palliative, low-toxicity treatment for patients with
advanced NSCLC is therefore needed and for this purpose the
epidermal growth factor receptor (EGFR/HER1) is a promising
target. Gefitinib (ZD 1839, Iressa; AstraZeneca, London, UK) is an
orally active, selective HER1-tyrosine kinase inhibitor (Wakeling
et al, 2002), which has been shown to elicit objective responses in
NSCLC cases, particularly in women nonsmokers with adeno-
carcinomas (Fukuoka et al, 2003; Kris et al, 2003). Recently, active
mutations of EGFR have been identified in such cases (Paez et al,
2004; Pao et al, 2004) and may be linked with the sensitivity to
gefitinib (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004).
However, the reason why mutations frequently occur in these
particular individuals is poorly understood.
Androgens are important hormones that play definitive roles in
the differentiation of males and females. They can modify the
activity of the epidermal growth factor network and EGFR
signaling is essential for androgen-induced proliferation (Klein
and Nielsen, 1993; Dammann et al, 2000; Torring et al, 2003). A
receptor for androgens has been reported to occur in NSCLCs
(Beattie et al, 1985; Kaiser et al, 1996) and there may be
cooperative interaction between the hormones and active muta-
tions of EGFR during the development of lung cancer. Previous
reports have suggested that smoking increases the levels of
androgens in men and women (Law et al, 1997; Trummer et al,
2002) and carcinogens from cigarette smoke may disrupt androgen
function by reducing androgen receptor (AR) levels in androgen-
responsive organs (Lin et al, 2004).
On the basis of these reports, we hypothesised that androgens
may play an important role in the efficacy of gefitinib in NSCLC
cases. In the present study, we therefore evaluated androgen levels
in patients treated with gefitinib and the relationship with clinical
efficacy.
PATIENTS AND METHODS
Between September 2002 and May 2004, 67 advanced or recurrent
NSCLC patients were analysed in this study. All 67 were treated
at our institution with gefitinib monotherapy (250mg oral doses
of gefitinib once daily) until disease progression occurred.
Response evaluation and confirmation were performed in
accordance with the WHO criteria (WHO, 1979). In brief, complete
response (CR) was defined as complete disappearance of all lesions
in imaging studies for at least 4 weeks without the appearance of
any new lesions. Partial response (PR) was defined as a 450%
decrease under the baseline in the sum of the products of the
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sperpendicular diameters of all measurable lesions and at least
stabilisation of all nonmeasurable lesions over a minimum period
of 4 weeks. Progressive disease (PD) was defined as a 425%
increase in the sum of the products of all measurable lesions, an
unequivocal increase of nonmeasurable disease, or the appearance
of new lesions. Cases were classified as having stable disease (SD) if
none of the criteria for classifying responses as a CR, PR, or PD
were met.
Blood was drawn before and during gefitinib administration. A
previous report indicated the median time to symptom improve-
ment with gefitinib to be only 8 days (Fukuoka et al, 2003), and we
therefore checked the hormone levels at days 14–18, when serum
was sampled between 10:00 and 14:00 and stored at 801C for
subsequent analyses. Serum levels of testosterone, dehydroepi-
androsterone (DHEA), and dehydroepiandrosterone sulphate
(DHEAS) were all measured at the SRL Laboratory (Tokyo, Japan).
For testosterone, an electrochemiluminescence immunoassay was
applied (ECLusys testosterone; Roche Diagnostics KK, Tokyo,
Japan) and radioimmunoassays were used for DHEA and DHEAS
(DPC DHEA and DPC DHEAS kits; Diagnostic Products Corpora-
tion, Los Angeles, CA, USA). The detection limits for testosterone,
DHEA, and DHEAS were 5, 0.2, and 20ngml
 1, respectively. Inter-
and intra-assay coefficients of variation were 6 and 8% for
testosterone, 8 and 9% for DHEA, and 4 and 4% for DHEAS,
respectively.
Appropriate ethical review boards approved the study, which
followed the recommendations of the Declaration of Helsinki for
biomedical research involving human subjects.
Statistical analysis
A paired t-test was used to compare the androgen levels between
the two time periods. Patients were grouped into responders (CR
and PR) and nonresponders (SD and PD) and the variables in each
group were compared with an unpaired t-test. All statistical
analyses were performed using SPSS version 8 statistical software
(SPSS Inc., IL, USA).
RESULTS
Patient characterisation
Data for patient characteristics are listed in Table 1. Of the 67, 31
(46.3%) were women. The median age was 61 years (range, 42–80
years). There were 26 patients (38.8%) who had never smoked and
adenocarcinoma was the primary histological finding in 56 cases
(83.6%). There was no prior chemotherapy in 16 (23.9%) of
the patients, and the remainder had received platinum-based
chemotherapy.
Response to treatment could only be evaluated in 64 of the 67
cases. We observed 20 PR (29.8%), and of these, 13 (65%) were
women and seven (35%) were men (P¼0.074). The median and
range of treatment duration with gefitinib were 2.1 and 0.2–21
months. In all, 10 (50%) of 20 responders and 29 (66%) of 44
nonresponders had a smoking history (P¼0.226).
Effects of gefitinib treatment on androgens levels in
NSCLC patients
Testosterone, DHEA, and DHEAS were detected in the serum of all
67 patients (see Table 2). There was a significant difference
observed between men and women for serum testosterone levels
(Po0.0001), but not for serum DHEA or DHEAS (DHEA;
P¼0.267, DHEAS; P¼0.0565).
In women, testosterone, DHEA, and DHEAS levels at pretreat-
ment were significantly higher than during treatment (testo-
sterone; P¼0.025, DHEA; P¼0.0065, DHEAS; P¼0.0326). In men,
pretreatment testosterone and DHEA levels were significantly
higher than during treatment, but there was no significant
difference for DHEAS (testosterone, P¼0.0009; DHEA,
P¼0.0085; DHEAS, P¼0.33). In addition, we compared hormone
levels between smokers and nonsmokers. Pretreatment, there were
no significant differences between women with and without a
smoking history. On the other hand, hormone levels were
significantly suppressed by gefitinib treatment in the 21 women
who had no smoking history (testosterone, P¼0.0016; DHEA,
Table 1 Patient characteristics
Variable No. of patients %
Total 67
Sex
Male 36 53.7
Female 31 46.3
Age (years)
Median 61
Range 42–80
Smoking history
Never 26 38.8
Former/current 41 61.2
Performance status
0, 1 48 71.6
42 19 28.4
Histology
Ad 56 83.6
Non-Ad 11 16.4
Stage
II–III 17 25.4
IV 27 40.3
Recurrence after surgery 23 34.3
Response
PR 20 29.8
SD/PD 44 64.7
NE 3 4.5
Prior chemotherapy
No 16 23.9
Yes 51 76.1
Ad¼adenocarcinoma; non-Ad¼nonadenocarcinoma; PR¼partial response;
SD¼stable disease; PD¼progressive disease; NE¼not evaluable.
Table 2 Androgen levels in patients treated with gefitinib
Pretreatment During treatment
Variable n Mean7s.d. n Mean7s.d. Paired t-test
Testosterone (ngml
 1)
Female 21.5712.0 31 13.8.0711.0 P¼0.025
Male 37 409.77129.8 37 350.87135.7 P¼0.0009
DHEA (ngml
 1)
Female 31 2.2172.03 31 1.3370.83 P¼0.0065
Male 37 1.7871.06 37 1.4970.92 P¼0.0085
DHEAS (ngml
 1)
Female 31 854.47579.5 31 645.87365.6 P¼0.0326
Male 37 1137.47607.7 37 1103.07601.5 P¼0.33
s.d.¼standard deviation; DHEA¼dehydroepiandrosterone;
DHEAS¼dehydroepiandrosterone sulphate.
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sP¼0.0157; DHEAS, P¼0.0441), but not in the 10 who had a
smoking history (testosterone, P¼0.6159; DHEA, P¼0.2487;
DHEAS, P¼0.4740). Figure 1 depicts the androgen levels for
women after dividing the group into responders vs nonresponders.
Testosterone, DHEA, and DHEAS levels in women responders
during treatment were significantly lower than those observed in
women nonresponders (testosterone, P¼0.007; DHEA, P¼0.046;
DHEAS, P¼0.029). When men were included in the analysis,
DHEA and DHEAS levels during treatment in the responders
(n¼20) were still significantly lower than in the nonresponders
(n¼44) (DHEA, P¼0.0324; DHEAS, P¼0.0447).
DISCUSSION
The present study of androgen levels (testosterone, DHEA, and
DHEAS) in advanced NSCLC patients treated with gefitinib
monotherapy revealed treatment-related decrease, especially in
women who had no smoking history. The clinical response of
gefitinib treatment appeared to be correlated with the suppression
of the hormone levels.
To our knowledge, there have been no previous reports of
effects of gefitinib treatment on levels of androgens in patients,
although a number of authors have examined relationships
between androgens and activity of the epidermal growth factor
network (Klein and Nielsen, 1993; Dammann et al, 2000; Torring
et al, 2003). There is evidence that EGFR expression is involved
in prostate cancer development and in progression to androgen
independence (Di Lorenzo et al, 2002), and an in vitro study
has provided evidence that androgens increase the EGFR levels in
androgen-sensitive prostate cancer cells and that EGFR signaling
is essential for androgen-induced proliferation and survival
(Torring et al, 2003). Although there has been no indication
of any relationship between androgens and EGFR in NSCLCs,
expression of ARs has been detected in NSCLC cell lines and
biopsy samples of primary lung cancers (Kaiser et al, 1996).
Additionally, expression has been detected more frequently in
women with adenocarcinoma, and thus this may be a prognostic
factor for use of gefitinib in NSCLCs (Fukuoka et al, 2003; Kris
et al, 2003; Miller et al, 2004). The data suggest that there is a
correlation between the AR and EGFR functions in lung cancer. In
agreement with this hypothesis, our results demonstrated clinical
responses to gefitinib treatment to correlate with suppression of
androgen levels.
One reason for lower androgen levels in responders than
nonresponders might be that smokers are resistant and have
higher androgen levels. However, there were no significant
difference in smoking history between responders and non-
responder in our study and there was no significant difference
of the pretreatment levels of androgens between smokers and
nonsmokers. On the other hand, gefitinib treatment significantly
suppressed androgen levels in women who had no smoking
history, but not in smokers. Smoking may disrupt the correlation
between EGFR and androgen.
Both gefitinib and androgens are metabolised by CYP3A4/5;
therefore, it can be speculated that gefitinib may affect the
metabolisms of androgens. On the other hand, there are no direct
evidences demonstrating PK interaction between gefitinib and
androgens. PK interaction between gefitinib and other drugs
metabolised by CY3A4/5 such as docetaxel or irinotecan were
reported (Fandi et al, 2003; Furman et al, 2004). These reports
suggested that gefitinib may decrease the clearance of these drugs
and it may be due to CYP3A4/5 substrate competition. If there are
any PK interactions between gefitinib and androgens, androgens
clearance may decrease and androgen levels may increase by
gefitinib treatment. However, we showed that gefitinib treatment
decreased the levels of androgens and it suggested that the effect
may not be due to change of CYP3A4/5 activity.
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Figure 1 Serum testosterone, DHEA, and DHEAS levels, pretreatment and during the gefitinib administration. Each androgen levels are depicted in
accordance to clinical response of gefitinib treatment (responders, PR; nonresponders, SD or PD). Error bars showed standard deviation.
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sWith single estimations of testosterone and DHEA, it is
necessary to take into account the circadian rhythms. In this
study, all blood was therefore taken at approximately the same
time, that is, between 10:00 and 14:00, although this does not
preclude any influence of cycles. On the other hand, several reports
have suggested that there is no circadian rhythm for serum DHEAS
levels (Molta and Schwartz, 1986; Hall et al, 1993; Kos-Kudla et al,
2001). Therefore, the differences seen in the DHEAS levels in this
study presumably reflect actual effects of gefitinib treatment. This
would suggest that the data for the other hormones might also
have clinical significance.
In conclusion, the results of the present small, retrospective
study indicate that androgen levels in NSCLC patients are affected
by gefitinib treatment and that they may be factors determining
sensitivity to this chemotherapeutic agent. Further large-scale
prospective trials are needed in the future to confirm these results
and to examine inter-relationships among androgens, smoking,
gefitinib sensitivity, and EGFR mutations.
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